Related Experiment Videos
APC0576: a novel small molecule, immunosuppressive agent effective in primate models
Kenji Yuzawa1, Atsushi Konishi, Kenji Takehana
1Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan. kyuzawa@md.tsukuba.ac.jp
Transplantation
|June 7, 2003
Summary
APC0576, a novel immunosuppressive agent, effectively reduced T-cell immune responses in vitro and in vivo primate models. This compound shows promise for treating organ transplant rejection and cytokine-mediated diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- APC0576 is a novel synthetic compound inhibiting NF-kappaB-dependent gene activation and chemokine synthesis.
- NF-kappaB is a key mediator in T-cell activation and immune responses.
Purpose of the Study:
- To investigate the effects of APC0576 on T-cell-dependent immune functions in vitro and in vivo.
- To evaluate APC0576's potential as an immunosuppressive therapeutic agent.
Main Methods:
- In vitro assays assessed APC0576's impact on human peripheral blood mononuclear cells' interleukin-2 production and proliferation.
- In vivo studies involved oral administration of APC0576 to rhesus monkeys immunized with tetanus toxoid or undergoing allogeneic kidney transplantation.
Main Results:
- APC0576 significantly suppressed interleukin-2 production and T-cell proliferation in vitro.
- In vivo, APC0576 dose-dependently attenuated T-cell-mediated immune responses, including antibody formation and delayed-type hypersensitivity, without observed toxicity.
- Allogeneic kidney transplants in monkeys showed sustained function during APC0576 treatment, with rejection occurring upon drug withdrawal.
Conclusions:
- APC0576 is an orally available immunosuppressive agent effective against T-cell-based immune responses.
- APC0576 demonstrates potential therapeutic applications in organ transplantation and cytokine-mediated inflammatory diseases.